PERRIGO CO PLC

Insight into Perrigo’s recent insider trades shows steady confidence, modest share buying, and neutral market impact—no looming shifts.

CEO insider activity shows CFO Guarita’s 141,376 RSUs reflect confidence in Perrigo’s rebound—an insider signal for investors to watch the 2027 vesting.

EVP & CSO Lennox Abigail’s July RSU purchase shows Perrigo leadership’s confidence, boosting long‑term upside and reinforcing investor trust.

Insider buying by Perrigo’s outgoing CEO signals confidence amid CEO change; investors gauge interim leadership’s impact on 2026 outlook.

Insider buying by Perrigo’s EVP signals confidence amid a 60% stock drop, offering investors a possible low‑price entry or early warning.

Insider buying at Perrigo signals confidence amid a 60% loss—read how executive trades could spark a rebound or warn of further decline.

Insider buying at €10.72 shows Perrigo’s executives see a turnaround, boosting confidence in its OTC and generic drug strategy. Explore the outlook and risks.

Insider trading at Perrigo Co PLC shows CEO Lockwood‑Taylor buying on a low €8.86 price, indicating confidence in the stock’s undervaluation and potential rebound.

Investor insight: CFO Guarita’s mixed buying and selling at Perrigo signals confidence yet strategic balance, highlighting insider moves that could spark a cautious rally.